Agilent Technologies Inc's Suppliers recorded an increase in sales by 15.85 % year on year in Q2 2026, sequentially sales grew by 4.62 %, Agilent Technologies Inc recorded an increase in cost of sales by 5.36 % year on year, relative to one quarter ago cost of sales fell by -0.82 % in Q2.
Agilent Technologies Inc's Suppliers recorded an increase in sales by 15.85 % year on year in Q2 2026, sequentially sales grew by 4.62 %, Agilent Technologies Inc recorded increase in cost of sales by 5.36 % year on year, compare to one quarter ago cost of sales fell by -0.82 % in Q2.
Agilent Technologies Inc's Comment on Supply Chain
The company supplies raw materials and assay development services to manufacturers in in vitro diagnostics, biotechnology, and pharmaceuticals. It partners with major pharmaceutical companies to develop tissue pharmacodiagnostics and companion diagnostics. Its genomics division provides reagents for next-generation sequencing workflows and arrays, supporting clinical laboratories in detecting DNA variants associated with genetic diseases and cancer therapies. The biomolecular analysis division delivers workflow solutions for nucleic acid sample quality control. The Life Sciences and Diagnostics Markets segment serves pharmaceutical, biopharmaceutical, diagnostics, clinical, academic, government, and applied markets, focusing on biopharmaceutical companies engaged in advanced therapeutic modalities such as cell and gene therapies by providing research tools and companion diagnostic development services. Additionally, the company offers contract development and manufacturing services for active pharmaceutical ingredients related to oligonucleotide-based therapeutics and specialized manufacturing for targeted therapeutics, including antibody production.
Agilent Technologies Inc's Comment on Supply Chain
The company supplies raw materials and assay development services to manufacturers in in vitro diagnostics, biotechnology, and pharmaceuticals. It partners with major pharmaceutical companies to develop tissue pharmacodiagnostics and companion diagnostics. Its genomics division provides reagents for next-generation sequencing workflows and arrays, supporting clinical laboratories in detecting DNA variants associated with genetic diseases and cancer therapies. The biomolecular analysis division delivers workflow solutions for nucleic acid sample quality control. The Life Sciences and Diagnostics Markets segment serves pharmaceutical, biopharmaceutical, diagnostics, clinical, academic, government, and applied markets, focusing on biopharmaceutical companies engaged in advanced therapeutic modalities such as cell and gene therapies by providing research tools and companion diagnostic development services. Additionally, the company offers contract development and manufacturing services for active pharmaceutical ingredients related to oligonucleotide-based therapeutics and specialized manufacturing for targeted therapeutics, including antibody production.
A's Suppliers Net Income grew by
A's Suppliers Net margin grew in Q2 to
70.34 %
12.64 %
A's Suppliers Net Income grew by 70.34 %
A's Suppliers Net margin grew in Q2 to 12.64 %
Agilent Technologies Inc's Suppliers Sales Growth
in Q2 2026 by Industry
Sources:
Agilent Technologies inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Agilent Technologies inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2.18 % 